The Genetic Pivot: How Biotech is Rewriting the Rules of the 2026 PipelineGlobal Report·5 hours agoCRVS-1.24%NVAX-2.04%
Renaissance Technologies LLC Takes $1.19 Million Position in Corvus Pharmaceuticals, Inc. $CRVSMarket Beat·Aug 14 at 03:32 AMCRVS-1.24%
Is Corvus Pharmaceuticals (CRVS) Undervalued After A Wider Q2 Loss?Simplywall·Aug 8 at 02:46 AMCRVS-1.24%
Corvus Pharmaceuticals (NASDAQ:CRVS) Posts Earnings Results, Misses Expectations By $0.03 EPSMarket Beat·Aug 7 at 11:41 PMCRVS-1.24%
Corvus publishes corporate presentation highlighting soquelitinib ITK inhibitor pipeline in immune disease and T-cell malignanciesPUBT·Aug 6 at 06:19 PMCRVS-1.24%
Corvus Q2 FY26 net loss widens to $18 million; R&D expense more than doubles to $16 millionPUBT·Aug 6 at 03:04 PMCRVS-1.24%
Corvus Pharmaceuticals schedules Q2 financial results conference call and webcastPUBT·Jul 30 at 03:14 PMCRVS-1.24%
Corvus Pharmaceuticals (CRVS) to Post Quarterly Earnings on ThursdayMarket Beat·Jul 30 at 05:41 AMCRVS-1.24%
Ian T. Clark resigns from Corvus board effective July 22, 2026TradingView·Jul 22 at 03:03 PMCRVS-1.24%
The Economy's Long Tail: What 10 Outliers Tell Us About the 2026 Market RealityGlobal Report·Jul 21 at 04:13 AMTOYO-6.90%ABCL-0.18%
10 Health Care Stocks With Whale Alerts In Today’s Sessionbenzinga_article·Jul 1 at 12:35 PMCRSP-3.85%PURR-0.21%
